WEBINARS AND EVENTS Maternal Malignancy Detection Through pcfDNA Screening Speakers: Marisa Jendras MMSc, CGC Lauren Eisemann MS, CGC Date: 04/23/2025 Duration: 1 hour CEU: Yes Please join us for this webinar where we will review pcfDNA result types that are suggestive of maternal malignancy and suggested follow up for patients with these findings. Summarize the use of cfDNA molecules in both oncology and prenatal genetic screens. Examine data related to the identification and management of maternal malignancy identified through pcfDNA screening. Outline ways specialties can work together when pcfDNA screening results indicate suspicion for maternal malignancy. Complete survey and quiz Hear from our Speakers Marisa Jendras MMSc, CGC Marisa is a certified genetic counselor with an MMSc in Genetic Counseling from Emory University. She practiced cancer and prenatal counseling in a clinical setting and later moved into a clinical pediatric setting. After 4.5 years of clinical practice, Marisa transitioned into an industry role with Myriad Genetics as a Medical Science Liaison with a focus on Women’s Health, including hereditary cancer risk assessment and prenatal screening. Lauren Eisemann MS, CGC Lauren is a genetic counselor and medical science liaison for Myriad Genetics. In the ten years that she has been with Myriad, she has covered much of the Northeast focused on reproductive genetics and hereditary cancer in the Ob/Gyn, MFM, genetic counseling and primary care landscape. Her recent role has shifted her into a team that is focused on work with key opinion leaders in the community, as well as research in the reproductive space. Prior to Myriad, Lauren was a genetic counselor at St. Joseph’s Hospital in Paterson, NJ, where she counseled patients around prenatal, pediatric and hereditary cancer genetics.